GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Price-to-Funds-From-Operations

AVEO Pharmaceuticals (STU:VPA1) Price-to-Funds-From-Operations : (As of Jun. 07, 2024)


View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


AVEO Pharmaceuticals (STU:VPA1) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.